Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274437 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL1163584 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4268324 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4282241 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL2722434 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL27946556 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4271266 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4274454 | 0.95 | TSHR (0.34) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4280281 | 0.95 | TSHR (0.34) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4272338 | 0.95 | TSHR (0.34) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654188-B2 | Glycotargeting therapeutics | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-05-23 | — | — | US | claimed |
| CN-115895651-A | Size-adjustable carbon dot and synthesis method and application thereof | 汕头大学 | 2023-04-04 | — | — | CN | claimed |
| CN-113502137-B | High-performance underwater adhesive gel based on sugar-containing polymer and preparation method thereof | 江南大学 | 2022-08-02 | — | — | CN | claimed |
| WO-2012057751-A1 | CROSSLINKED CELLULOSIC POLYMERS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2012-05-03 | — | — | WO | claimed |
| US-20120108678-A1 | BRANCHED COPOLYMERS, COMPOSITIONS AND USES | UNILEVER PLC (GB) | 2012-05-03 | — | — | US | claimed |
| US-20110034602-A1 | Thixotropic reactive composition | SIKA TECHNOLOGY AG (CH) | 2011-02-10 | — | — | US | claimed |
| WO-2010089571-A1 | BRANCHED COPOLYMERS, COMPOSITIONS AND USES | UNILEVER PLC (GB) | 2010-08-12 | — | — | WO | claimed |
| WO-2010089576-A1 | BRANCHED COPOLYMERS, COMPOSITION AND USES | UNILEVER PLC (GB) | 2010-08-12 | — | — | WO | claimed |
| US-20090294362-A1 | STATIONARY PHASE FOR HYDROPHILIC INTERACTION CHROMATOGRAPHY | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | claimed |
| US-20080161504-A1 | Thixotropic Reactive Composition | SIKA TECHNOLOGY AG (CH) | 2008-07-03 | — | — | US | claimed |
| EP-0251348-A1 | Water-soluble saccharide polymers | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-01-07 | — | — | EP | claimed |
| JP-57026746-A | — | — | None | — | — | JP | disclosed |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-04-30 | — | — | US | disclosed |
| US-20260034226-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20250295743-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-0611783-A1 | Copolymers of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives | CIBA-GEIGY AG (CH) | 1994-08-24 | — | — | EP | disclosed |
| US-5288827-A | Drug selivery | CIBA-GEIGY CORPORATION (US) | 1994-02-22 | — | — | US | disclosed |
| US-4725524-A | Dry film resist and production of resist images | BASF AKTIENGESELLSCHAFT (DE) | 1988-02-16 | — | — | US | disclosed |
| US-4714751-A | Crosslinkable resin, photosensitive recording material based on this crosslinkable resin, and production of a lithographic printing plate using this photosensitive recording material | BASF AKTIENGESELLSCHAFT (DE) | 1987-12-22 | — | — | US | disclosed |
| JP-S5726746-A | DETERMINING METHOD OF HEMOGLOBIN BOUND TO GLUCOSE | SEKISUI CHEM CO LTD | 1982-02-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295743-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885L3MBTL1 2270/4885ALDH1A1 2577/4885 |
| US-20260034226-A1 | GLYCOTARGETING THERAPEUTICS | LGALS1, ST6GAL1, LGALS2 | LMNA 4291/4885L3MBTL1 1057/4885ALDH1A1 460/4885 |
| US-11654188-B2 | Glycotargeting therapeutics | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885L3MBTL1 2270/4885ALDH1A1 2577/4885 |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | CD74, HLA-DRB1, CD69 | LMNA 4625/4885L3MBTL1 2352/4885ALDH1A1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.